@article{oai:kanazawa-u.repo.nii.ac.jp:00013729,
 author = {Ishiyama, Ken and Takami, Akiyoshi and Kanda, Yoshinobu and Nakao, Shinji and Hidaka, Michihiro and Maeda, Tetsuo and Naoe, Tomoki and Taniguchi, Shuichi and Kawa, Keisei and Nagamura, Tokiko and Atsuta, Yoshiko and Sakamaki, Hisashi},
 issue = {3},
 journal = {Leukemia},
 month = {Mar},
 note = {Acute myeloid leukemia (AML) with t(6;9)(p23;q34) is well known to have a poor prognosis treated with chemotherapy and autotransplantation. The presence of this karyotype is an indicator for allogeneic hematopoietic stem cell transplantation (HSCT); however, the impact of t(6;9)(p23;q34) on the HSCT outcome remains unclear. We conducted a matched-pair analysis of de novo AML patients with and without t(6;9)(p23;q34) using data obtained from the Japanese HSCT data registry. A total of 57 patients with t(6;9)(p23;q34) received transplants between 1996 and 2007, and 171 of 2056 normal karyotype patients matched for age, disease status at HSCT and graft source were selected. The overall survival, disease-free survival, cumulative incidence of relapse and the non-relapse mortality in t(6;9)(p23;q34) patients were comparable to those for normal karyotype patients. A univariate analysis showed that t(6;9)(p23;q34) had no significant impact on the overall survival. These findings suggest that allogeneic HSCT may overcome the unfavorable impact of t(6;9)(p23;q34) as an independent prognostic factor. © 2012 Macmillan Publishers Limited All rights reserved.},
 pages = {461--464},
 title = {Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: A matched-pair analysis},
 volume = {26},
 year = {2012}
}